BCL3 and cancer: Notwithstanding its inability to drive EMT, BCL3’s impact as a permissive regulator of cell migration encompasses a spectrum of motility phenotypes whereby suppression of BCL3 results in the inhibition of both constitutive and EMT-acquired cell motility, restricting all forms of cancer cell motility in a non-redundant manner [112].